Friday, March 22, 2013
Bioheart Inc., of Sunrise, Fla., said it secured sufficient funding to begin the Phase I ANGEL safety and efficacy trial of LipiCell (adipose-derived stem cells) in congestive heart failure.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.